These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

738 related items for PubMed ID: 22339676

  • 21. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.
    BMC Cancer; 2012 May 04; 12():166. PubMed ID: 22559167
    [Abstract] [Full Text] [Related]

  • 22. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
    Que W, Li S, Chen J.
    Mol Med Rep; 2013 May 04; 7(5):1641-5. PubMed ID: 23545701
    [Abstract] [Full Text] [Related]

  • 23. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
    Park J, Bae EK, Lee C, Choi JH, Jung WJ, Ahn KS, Yoon SS.
    BMB Rep; 2014 May 04; 47(5):274-9. PubMed ID: 24286313
    [Abstract] [Full Text] [Related]

  • 24. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
    Du HF, Yu LJ, Meng YF, Lv HY, Meng J, Song XN, Zhang JQ.
    Leuk Lymphoma; 2013 Mar 04; 54(3):607-18. PubMed ID: 22889356
    [Abstract] [Full Text] [Related]

  • 25. Signal transducer and activator of transcription 3 pathway mediates genipin-induced apoptosis in U266 multiple myeloma cells.
    Lee JC, Ahn KS, Jeong SJ, Jung JH, Kwon TR, Rhee YH, Kim SH, Kim SY, Yoon HJ, Zhu S, Chen CY, Kim SH.
    J Cell Biochem; 2011 Jun 04; 112(6):1552-62. PubMed ID: 21344490
    [Abstract] [Full Text] [Related]

  • 26. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma.
    Baumann P, Mandl-Weber S, Oduncu F, Schmidmaier R.
    Exp Cell Res; 2009 Feb 01; 315(3):485-97. PubMed ID: 19071109
    [Abstract] [Full Text] [Related]

  • 27. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
    Elmahi AY, Niu C, Li W, Li D, Wang GJ, Hao SS, Cui JW.
    Asian Pac J Cancer Prev; 2013 Feb 01; 14(11):6469-73. PubMed ID: 24377552
    [Abstract] [Full Text] [Related]

  • 28. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M.
    Cancer Sci; 2015 Apr 01; 106(4):438-46. PubMed ID: 25613668
    [Abstract] [Full Text] [Related]

  • 29. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
    Balsas P, Galán-Malo P, Marzo I, Naval J.
    Leuk Res; 2012 Feb 01; 36(2):212-8. PubMed ID: 21978467
    [Abstract] [Full Text] [Related]

  • 30. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.
    Cancer Res; 2007 Jun 01; 67(11):5418-24. PubMed ID: 17545623
    [Abstract] [Full Text] [Related]

  • 31. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F, Xia B, Li X, Guo S, Zhang L, Tian C, Yu Y, Zhang Y.
    Zhonghua Zhong Liu Za Zhi; 2015 Jun 01; 37(6):412-7. PubMed ID: 26463142
    [Abstract] [Full Text] [Related]

  • 32. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
    Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL.
    Cancer Res; 2008 Aug 15; 68(16):6698-707. PubMed ID: 18701494
    [Abstract] [Full Text] [Related]

  • 33. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
    Liu S, Zhang Y, Huang C, Lin S.
    J Cell Biochem; 2020 Feb 15; 121(2):1475-1490. PubMed ID: 31498483
    [Abstract] [Full Text] [Related]

  • 34. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
    Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ.
    Clin Cancer Res; 2007 Nov 01; 13(21):6469-78. PubMed ID: 17975159
    [Abstract] [Full Text] [Related]

  • 35. [Effect of 20 (S)-ginsenoside Rg3 on the proliferation inhibition and secretion of vascular endothelial growth factor of multiple myeloma cell line U266].
    Song Y, Hou J, Kang L, Gao S.
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jun 01; 35(6):519-23. PubMed ID: 24985176
    [Abstract] [Full Text] [Related]

  • 36. 2,4-Dihydroxy-3'-methoxy-4'-ethoxychalcone suppresses cell proliferation and induces apoptosis of multiple myeloma via the PI3K/akt/mTOR signaling pathway.
    Zhu F, Jiang D, Zhang M, Zhao B.
    Pharm Biol; 2019 Dec 01; 57(1):641-648. PubMed ID: 31564190
    [Abstract] [Full Text] [Related]

  • 37. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L, Ma YP, Jia G.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov 01; 33(11):926-31. PubMed ID: 23363750
    [Abstract] [Full Text] [Related]

  • 38. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway.
    Li J, Liu Z, Li Y, Jing Q, Wang H, Liu H, Chen J, Feng J, Shao Q, Fu R.
    J Investig Med; 2019 Jan 01; 67(1):39-47. PubMed ID: 29997148
    [Abstract] [Full Text] [Related]

  • 39. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
    Yang M, Huang J, Pan HZ, Jin J.
    Int J Mol Med; 2008 Oct 01; 22(4):489-96. PubMed ID: 18813856
    [Abstract] [Full Text] [Related]

  • 40. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ, Lin YJ, Liu XJ, Shang BY, Zhen YS.
    Anticancer Drugs; 2013 Jul 01; 24(6):609-16. PubMed ID: 23698252
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.